

PRESS RELEASE 26 April 2023 11:40:00 CEST

Senzime announces connectivity with the Masimo Hospital Automation[™] platform

Uppsala, April 26, 2023. Senzime AB (publ) today presented the launch of TetraGraph® Xcom connectivity with the Masimo Hospital Automation[™] platform, an integration that enables the automatic transfer of neuromuscular data from TetraGraph through a Masimo connectivity hub and into a patient's medical records.

Interconnected medical devices are essential resources in the delivery of patient care and play a significant role in improving clinician workflows.

"The launch of the Xcom integration is the first step in our connectivity agreement with Masimo. The agreement is a major milestone for us, and we are working hard to ensure that we do our utmost to help healthcare providers worldwide to improve workflows and save time, with the ultimate goal of ensuring patient safety," said Pia Renaudin, CEO of Senzime.

About TetraGraph®

TetraGraph is a quantitative neuromuscular monitor, based on the gold standard electromyography (EMG) technology which provides accurate and versatile monitoring of neuromuscular blockade. The product is designed to meet the needs of monitoring physiological data during surgery of patients receiving general anesthesia and muscle relaxation using muscle paralyzing drugs. TetraGraph stimulates the patient's peripheral nerve using the TetraSens® disposable sensors and measures, analyzes, and displays the muscle's potential in real time. Thanks to its small size and versatile features, TetraGraph can be used in any type of surgery, anywhere in the hospital environment, and can be connected to external monitors and electronic hospital records.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation[™] platform, and include Iris® Gateway, iSirona[™], Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60[™], and Masimo SafetyNet®. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB Phone: +46 (0) 708 13 34 17, e-mail: pia.renaudin@senzime.com

Paula Treutiger, Head of Communication and IR Phone: +46 (0) 733 66 65 99, e-mail: paula.treutiger@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDAcleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at **senzime.com**.

Attachments

Senzime announces connectivity with the Masimo Hospital Automation[™] platform